HER2 tumor marker tests are used to determine whether breast cancer is HER2 positive or negative. A person is a candidate for ...

The global HER2-positive breast cancer market is rapidly evolving due to rising prevalence and demand for targeted therapies. HER2-positive breast cancer, characterized by overexpression of HER2 ...

During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone ...

A new nanozyme-antibody platform selectively targets HER2-positive tumors, disrupting gene expression and reducing metastasis ...

June brought major breast cancer updates, and CURE is sharing the latest treatment combinations, biomarker-driven care and ...

At the recent American Society of Clinical Oncology (ASCO) annual meeting, interim results from the DESTINY-Breast09 trial ...

Key Takeaways Metastatic breast cancer subtypes and biomarkers are crucial for guiding treatment decisions and managing disease progression. ER-positive, HER2-negative breast cancer treatment often ...

Discover the latest advancements in breast cancer treatment at the 24th Annual International Congress, featuring expert ...

Breast cancer patients may have inferior recurrence-free survival after neoadjuvant chemotherapy if they are overweight or obese at diagnosis.

Omitting carboplatin from neoadjuvant treatment can improve safety without compromising efficacy in patients with HER2-positive early breast cancer.

The official results of the BRACELET-01 (PrECOG 0113) trial have been published in Clinical Cancer Research, detailing the ...

Azhar W, Cossyleon R, Kamal SF, Delfino K, Robinson K, Rao K. Characteristics, treatment, and survival of male breast cancer: a 21-year retrospective analysis at a community academic institute in ...